A recent study from UT Health San Antonio, involving over 2,400 older adults, has identified a significant biological relationship between extended sleep duration and elevated levels of phosphorylated tau 181 (p-tau181), a protein associated with Alzheimer’s disease. Researchers discovered that regular sleep durations of 8.5 hours or more per night correlate with higher blood concentrations of p-tau181, particularly escalating beyond 10 hours. This suggests that longer sleep might reflect early neurodegenerative processes rather than directly causing cognitive decline.
Read More
The study employed non-linear mathematical modeling to analyze self-reported sleep habits and blood biomarker data, revealing that p-tau181 levels began to rise notably at sleep durations of 8.5 to 9 hours per night. The team found that p-tau181 remained a reliable indicator of Alzheimer's-related changes, while associations with other proteins dissipated after accounting for kidney function.
Dr. Vanessa M. Young, the lead author, emphasized that this study is a snapshot rather than a long-term analysis. Therefore, while long sleep duration is associated with elevated p-tau181 levels, it should not be perceived as a direct causative factor for Alzheimer's. Instead, excessive sleep may indicate the brain's response to early neurodegenerative changes. She noted that individuals who consistently require 9 to 10 hours of sleep should consider discussing their sleep patterns with a healthcare provider as it may warrant monitoring and evaluation.
This research builds on a previous study from 2025 demonstrating a link between longer sleep duration and diminished cognitive performance, especially in individuals with depression. The Framingham Heart Study participants had an average age of 70, representing a diverse cohort suitable for examining these complex relationships.
The overall findings underscore the need for ongoing research into sleep as a modifiable risk factor in Alzheimer’s disease. The study concludes that long sleep duration may serve as a potential behavioral marker for increased p-tau181 levels, which could assist in risk assessment and necessitate further investigation. The article is published in Alzheimer’s & Dementia, the Journal of the Alzheimer’s Association.